Development and characterization of cell models harbouring mtDNA deletions for in vitro study of Pearson syndrome
Author(s) -
Carmen HernándezAinsa,
Ester LópezGallardo,
Maria Concepción GarcíaJiménez,
Francisco José Climent-Alcalá,
Carmen RodríguezVigil,
Marta García Fernández de Villalta,
Rafael Artuch,
Julio Montoya,
Eduardo RuizPesini,
Sonia Emperador
Publication year - 2022
Publication title -
disease models and mechanisms
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.327
H-Index - 83
eISSN - 1754-8411
pISSN - 1754-8403
DOI - 10.1242/dmm.049083
Subject(s) - heteroplasmy , induced pluripotent stem cell , biology , mitochondrial dna , mitochondrion , in vitro , oxidative phosphorylation , mitochondrial disease , genetics , microbiology and biotechnology , bioinformatics , gene , biochemistry , embryonic stem cell
Pearson syndrome is a rare multisystem disease caused by single large-scale mitochondrial DNA deletions (SLSMDs). The syndrome presents early in infancy and is mainly characterised by refractory sideroblastic anaemia. Prognosis is poor and treatment is supportive, thus the development of new models for the study of Pearson syndrome and new therapy strategies is essential. In this work, we report three different cell models carrying an SLMSD: fibroblasts, transmitochondrial cybrids and induced pluripotent stem cells (iPSCs). All studied models exhibited an aberrant mitochondrial ultrastructure and defective oxidative phosphorylation system function, showing a decrease in different parameters, such as mitochondrial ATP, respiratory complex IV activity and quantity or oxygen consumption. Despite this, iPSCs harbouring ‘common deletion’ were able to differentiate into three germ layers. Additionally, cybrid clones only showed mitochondrial dysfunction when heteroplasmy level reached 70%. Some differences observed among models may depend on their metabolic profile; therefore, we consider that these three models are useful for the in vitro study of Pearson syndrome, as well as for testing new specific therapies. This article has an associated First Person interview with the first author of the paper.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom